Cargando…

Effect of risedronate on bone loss at discontinuation of denosumab

PURPOSE: The occurrence of multiple vertebral fractures was reported after denosumab discontinuation. The use of bisphosphonates following denosumab has been suggested to prevent this bone loss. The aim of our observational trial was to evaluate the ability of risedronate to prevent the bone loss re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laroche, Michel, Couture, Guillaume, Ruyssen-Witrand, Adeline, Constantin, Arnaud, Degboé, Yannick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371752/ https://www.ncbi.nlm.nih.gov/pubmed/32715031 http://dx.doi.org/10.1016/j.bonr.2020.100290

Ejemplares similares

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
por: Laroche, Michel, et al.
Publicado: (2023)

Hypophosphatasia: A Case of Two Patients With Spinal Cord Compression From Increase in Ligamentous Ossifications During Treatment
por: Laroche, Michel, et al.
Publicado: (2021)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study
por: Degboé, Yannick, et al.
Publicado: (2022)

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
por: Champs, Bénédicte, et al.
Publicado: (2019)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort data
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2019)

Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2017)

Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism
por: Degboé, Yannick, et al.
Publicado: (2019)

Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2023)

Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database
por: Carlé, Caroline, et al.
Publicado: (2023)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort
por: Degboé, Yannick, et al.
Publicado: (2015)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2016)

Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
por: Rauwel, B., et al.
Publicado: (2020)

Genetic markers as a predictive tool based on statistics in medical practice: ethical considerations through the analysis of the use of HLA-B(*)27 in rheumatology in France
por: Colineaux, Hélène, et al.
Publicado: (2015)

Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort
por: López-Medina, Clementina, et al.
Publicado: (2019)

Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats
por: Ye, Tingjun, et al.
Publicado: (2017)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Retraction: Effect of Pre- and Post-Surgery Treatment with Risedronate on Trabecular Bone Loss in Ovariectomized Rats
por: IWAMOTO, Jun, et al.
Publicado: (2018)

Risedronate-loaded aerogel scaffolds for bone regeneration
por: El-Wakil, Nahla, et al.
Publicado: (2022)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
por: Lee, Chia-Che, et al.
Publicado: (2021)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
por: Davidoff, Dahlia F, et al.
Publicado: (2020)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
por: Vinson, D., et al.
Publicado: (2020)

Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice
por: Omiya, Toshinobu, et al.
Publicado: (2020)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
por: Tay, Wei Lin, et al.
Publicado: (2022)

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
por: Jähn-Rickert, Katharina, et al.
Publicado: (2020)

Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits
por: Aghayan, Shabnam, et al.
Publicado: (2021)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort
por: Carvalho, Pedro D, et al.
Publicado: (2020)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement: A systematic review and meta-analysis
por: Ren, Liang, et al.
Publicado: (2018)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m67jfffuv5idll5jueb81tf1vj